Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide)

Author： Felberbaum RE Küpker W Krapp M Gehl B Ludwig M Diedrich K

Publisher： Reproductive Healthcare Ltd

ISSN： 1472-6483

Source： Reproductive BioMedicine Online, Vol.3, Iss.1, 2001-07, pp. : 14-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

By Mongiat-Artus Pierre Teillac Pierre

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2171-2179

Informa Healthcare

Access to resources Recommend Favorite

Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins

By Ulloa-Aguirre Alfredo Timossi Carlos

Reproductive BioMedicine Online, Vol. 1, Iss. 2, 2000-10 ,pp. : 48-62

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

By Felberbaum Ricardo E Diedrich Klaus

Reproductive BioMedicine Online, Vol. 6, Iss. 1, 2003-01 ,pp. : 43-53

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action

By Ortmann O Weiss JM Diedrich K

Reproductive BioMedicine Online, Vol. 5, Iss. 3, 2002-11 ,pp. : 1-7

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane Review

By Al-Inany HG Abou-Setta AM Aboulghar M

Reproductive BioMedicine Online, Vol. 14, Iss. 5, 2007-05 ,pp. : 640-649

Reproductive Healthcare Ltd

Access to resources Recommend Favorite